Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$970K Buy
3,854
+4
+0.1% +$861 0.48% 26
2026
Q1
$837K Buy
3,850
+48
+1% +$10.6K 0.49% 24
2025
Q4
$869K Sell
3,802
-7
-0.2% -$1.59K 0.5% 25
2025
Q3
$882K Hold
3,809
0.53% 24
2025
Q2
$707K Buy
3,809
+174
+5% +$32.3K 0.45% 25
2025
Q1
$762K Hold
3,635
0.53% 23
2024
Q4
$646K Buy
3,635
+75
+2% +$13.8K 0.44% 24
2024
Q3
$703K Sell
3,560
-177
-5% -$33K 0.49% 22
2024
Q2
$641K Sell
3,737
-357
-9% -$59.1K 0.49% 24
2024
Q1
$746K Sell
4,094
-108
-3% -$18.6K 0.59% 20
2023
Q4
$651K Hold
4,202
0.54% 23
2023
Q3
$593K Hold
4,202
0.57% 24
2023
Q2
$567K Buy
+4,202
New +$616K 0.52% 27

Other funds holding ABBV

Michael S. Ryan Inc's ABBV Position: Q2 2026 in Review

Michael S. Ryan Inc increased its AbbVie (ABBV) stake by 0.1% in Q2 2026, buying an estimated $861 and bringing the position to 3,854 shares worth $970K. The position accounts for 0.48% of the portfolio, ranked #26.

Michael S. Ryan Inc first reported a position in ABBV in Q2 2023 and has held it in 13 quarters since. 2,017 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Michael S. Ryan Inc held 3,854 shares of AbbVie worth $970K as of Q2 2026.
  • Michael S. Ryan Inc bought 4 AbbVie shares in Q2 2026, an estimated $861.
  • AbbVie made up 0.48% of Michael S. Ryan Inc's portfolio in Q2 2026, its #26 holding.
  • Michael S. Ryan Inc first reported a position in AbbVie in Q2 2023 and has held it in 13 quarters since.
  • 2,017 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Michael S. Ryan Inc's 13F filing for Q2 2026, filed 1 Jul 2026.